Windy Cole
HPTC is supported by multiple clinical studies that demonstrate efficacy across multiple hard-to-heal and acute wound types. Preservation of native collagen architecture, absence of chemical crosslinking, physiologically relevant scaffold structure and favourable safety and economic profiles collectively support its role as an evidencebased advanced wound therapy. Evidence supports HPTC's clinical utility and integration into routine wound care practice for management of complex wounds. These findings validate HPTC's medical necessity and economic value, underscoring its status as an advanced wound therapy with emerging supportive evidence rather than an experimental or investigational intervention.
BACKGROUND: Hard-to-heal wounds remain a major healthcare challenge due to persistent inflammation, extracellular matrix (ECM) degradation, impaired angiogenesis and failure to progress through normal healing pathways. Standard wound care alone often fails to achieve timely wound closure, necessitating biologically active therapies that restore the wound microenvironment. High-purity type I collagen (HPTC) (Helicoll, EnColl Corp, Fremont, CA, US) is a uncrosslinked skin substitute designed to function as a biologically active ECM scaffold that supports tissue regeneration rather than serving solely as a passive wound covering.
METHODS: A comprehensive literature review was conducted of the clinical, mechanistic, technical and economic evidence supporting HPTC. The evidence base included six randomised controlled trials (RCTs), pooled analyses, comparative studies, observational investigations and health-economic evaluations spanning diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers (PUs), burns, donor sites, surgical wounds and complex wounds.
RESULTS: Across hard-to-heal wound studies, HPTC consistently demonstrated improved healing outcomes compared with active comparators and standard therapies. DFU studies demonstrated complete closure rates up to 83.3% compared with approximately 51.7% in comparator groups, with ≥50% wound reduction observed in 85-88% of patients at 4 weeks. VLU studies demonstrated closure rates approaching 70% compared with 43.3% for comparators, while PU studies demonstrated closure rates of approximately 75%. Mechanistically, preserved native collagen structure enabled physiological cell adhesion, growth factor binding, protease modulation, angiogenesis, fibroblast recruitment and ECM restoration. No significant safety concerns or serious adverse events attributable to HPTC were reported. Economic analyses further demonstrated favourable cost-effectiveness, reduced application frequency and lower overall treatment costs relative to competing advanced wound therapies.
CONCLUSIONS: HPTC is supported by multiple clinical studies that demonstrate efficacy across multiple hard-to-heal and acute wound types. Preservation of native collagen architecture, absence of chemical crosslinking, physiologically relevant scaffold structure and favourable safety and economic profiles collectively support its role as an evidencebased advanced wound therapy. Evidence supports HPTC's clinical utility and integration into routine wound care practice for management of complex wounds. These findings validate HPTC's medical necessity and economic value, underscoring its status as an advanced wound therapy with emerging supportive evidence rather than an experimental or investigational intervention.
STATEMENT OF INTEREST: Funding for the preparation of this manuscript was provided by Encoll Corp (Fremont, CA, US), manufacturer of HPTC. The author reports receiving support related to development of this review. The sponsor reviewed the manuscript for scientific accuracy but did not control the final interpretation or conclusions.